SUNHO BIO-B (02898) has announced that on April 30, 2026, the company received a letter from the Stock Exchange containing the following guidance for the resumption of share trading: (a) conduct an appropriate independent forensic investigation into service agreements and any other payments of a similar nature or that raise similar concerns, assess the impact on the company's business operations and financial condition, disclose the investigation findings, and implement appropriate remedial measures; (b) demonstrate that there are no reasonable regulatory concerns regarding the integrity, competence, and/or character of the Group's management and/or any individuals with significant influence over the company's management and operations, which could pose risks to investors and damage market confidence; (c) appoint an independent internal control advisor to conduct an independent internal control review, and demonstrate that: (i) the identified material deficiencies related to the trading suspension have been rectified, and all necessary remedial measures have been implemented; and (ii) the company's internal controls are sufficient and effective for their purpose, enabling the issuer to comply with the Listing Rules in all material respects, including but not limited to financial reporting, cash management, disclosure and compliance concerning discloseable and connected transactions, and the disclosure of material information; (d) publish all outstanding financial results required by the Listing Rules and address any audit qualifications; (e) demonstrate that the company complies with Listing Rule 13.24; and (f) inform the market of all material information to enable the company's shareholders and investors to assess its condition. The Exchange may amend the resumption guidance from time to time if the company's circumstances change. According to Listing Rule 6.01A, if the shares have been suspended for 18 consecutive months, the Exchange may delist the company. The 18-month period will expire on September 30, 2027. If the company fails to remedy the issues leading to the suspension, fulfill the resumption guidance, and fully comply with the Listing Rules to the satisfaction of the Exchange, thereby resuming share trading, by September 30, 2027, the Listing Division of the Exchange will recommend the Listing Committee to commence procedures to cancel the company's listing status. Under Listing Rules 6.01 and 6.10, the Exchange also has the authority to impose a specific shorter remedial period where appropriate. Pursuant to Listing Rule 3A.19, Somerley Capital Limited has been appointed as the company's compliance advisor to provide guidance and advice on compliance with the Listing Rules and other applicable laws and regulations during the period following its listing and until the publication of its financial results for the first full financial year. Given the current circumstances, and during the period Somerley is appointed as the company's compliance advisor (or any replacement under Rule 3A.27), the company expects to actively engage with and involve Somerley during the remedial period to achieve re-compliance and fulfill the resumption guidance. The company has been making its best efforts to resolve these matters, remedy the issues leading to the suspension, fulfill the resumption guidance, and fully comply with the Listing Rules to the satisfaction of the Exchange to resume trading of its shares. The company will make further announcements in due course as required by the Listing Rules. The company's shares will continue to be suspended from trading.